Ultragenyx Pharmaceutical
RARE
#3682
Rank
โ‚น315.06 B
Marketcap
โ‚น3,266
Share price
0.56%
Change (1 day)
-21.24%
Change (1 year)

Earnings for Ultragenyx Pharmaceutical (RARE)

Earnings in 2025 (TTM): -โ‚น44.95 Billion

According to Ultragenyx Pharmaceutical's latest financial reports the company's current earnings are โ‚น0.63 Billion. In 2024 the company made an earning of -โ‚น45.52 Billion, an increase over its 2023 earnings that were of -โ‚น48.94 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Ultragenyx Pharmaceutical from 2013 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -โ‚น44.95 Billion-1.24%
2024 -โ‚น45.52 Billion-6.99%
2023 -โ‚น48.94 Billion-17.65%
2022 -โ‚น59.43 Billion55.52%
2021 -โ‚น38.21 Billion178.53%
2020 -โ‚น13.72 Billion-59.64%
2019 -โ‚น34 Billion1.46%
2018 -โ‚น33.51 Billion12.9%
2017 -โ‚น29.68 Billion32.63%
2016 -โ‚น22.38 Billion67.87%
2015 -โ‚น13.33 Billion160.2%
2014 -โ‚น5.13 Billion66.64%
2013 -โ‚น3.08 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
BioMarin Pharmaceutical
BMRN
โ‚น61.27 B-230.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
โ‚น0.44 B-100.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Esperion Therapeutics
ESPR
-โ‚น2.48 Billion-94.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Lexicon Pharmaceuticals
LXRX
-โ‚น6.19 Billion-86.78%๐Ÿ‡บ๐Ÿ‡ธ USA